MedTrace Logo

Nutrition Blood Outcomes Following Tocotrienol N2B

NCT01858311 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-09-20

No results posted yet for this study

Summary

A natural form of vitamin E called tocotrienol (TCT) has blood thinning and cholesterol lowering properties, both of which may benefit stroke survivors. This study is being conducted to determine the blood thinning and cholesterol lowering properties of TCT in stroke or TIA (transient ischemic attack, which is also referred to as a "mini-stroke") survivors that are receiving the standard treatment for prevention of recurrent stroke.

Study Hypothesis: Oral TCT decreases the incidence of aspirin and clopidogrel nonresponders, increases the extent of inhibition of platelet aggregation, and decreases LDL without significant side effects in stroke patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

Tocotrienol Capsules

Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)

OTHER

Placebo Vehicle

Placebo capsules per day (2 in the morning and 2 in the evening)

Sponsors & Collaborators

  • Malaysia Palm Oil Board

    collaborator OTHER_GOV

  • Ohio State University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2018-09-30
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01858311 on ClinicalTrials.gov